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Objective: Medication adherence is extremely important in preventing relapse and
lowering symptoms in schizophrenic patients. However, estimates show that nearly
half of these patients have poor adherence. The Brief Adherence Rating Scale (BARS)
seems to be the most reliable tool assessing adherence in schizophrenia and shows
that the antipsychotic adherence ratio (AAR) is about 49.5% in schizophrenia. The aim
of the study was to test if an electronic pill dispenser named DoPill® improved AAR of
schizophrenic patients. Furthermore, we compared AAR obtained by the DoPill® and the
BARS, in order to verify whether the DoPill® provides reliable assessment of medication
adherence.
Methods: The DoPill® is a smart pill dispenser that beeps and ﬂashes at the appropriate
time of the day. Each of its 28 compartments is covered by a plastic lamina that, when
taken off, sends a signal to the pharmacist. Patients were randomized to the DoPill® or
treatment as usual groups for 6 weeks. The BARS was used as a reference measure.
Results: Forty-six percent of patients were deemed to be non-adherent with antipsychotic
medication. The mean AAR was 67% after 6 weeks. DoPill® recorded better AAR than
some of those found in the literature and were lower than the BARS estimate we found.
Conclusion:These results suggest that DoPill® is a valid tool that providesmore reliable and
objective data for the clinician about their patient’s adherence, than existing assessment
tools like the BARS. Furthermore, the device may help patients successfully manage their
medication regimen.
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INTRODUCTION
The ﬁrst decade of illness in schizophrenic patients is often
characterized by repeated episodes of psychosis with vary-
ing levels of remission between episodes and increased dis-
ability following each episode, especially when untreated by
antipsychotic medication (Ciompi, 1980; Wyatt, 1991; Tan-
don et al., 2009; Malla et al., 2011). Despite the established
beneﬁts of antipsychotic therapy in schizophrenia, all three
components of adherence are affected: initiation, implemen-
tation, and discontinuation (Vrijens et al., 2012). Data from
2,588 ﬁrst-episode psychosis (FEP) patients revealed both ini-
tiation and discontinuation non-adherence: only 58% collected
Abbreviations: AAR, antipsychotic adherence ratio; BARS, Brief Adherence Rating
Scale; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders IV; EET,
Enriched Environment with Technology; FEP, ﬁrst-episode psychosis; LCD, liquid
crystal display; MEMS®, Medication Events Monitoring System; PANSS, positive
and negative syndrome scale for schizophrenia; TAU, treatment as usual group.
their prescription during the ﬁrst 30 days of hospital discharge
and only 46% continued their initial treatment for 30 days
or longer (Tiihonen et al., 2011). The implementation com-
ponent of non-adherence was studied in a semi-quantitative
review of the literature which found that 49.5% of patients with
schizophrenia were deemed non-adherent according to the crite-
ria: “taking medications as prescribed at least 75% of the time”
and 41.2% were deemed non-adherent according to the crite-
ria: “regularly taking medications as prescribed” (Lacro et al.,
2002). In practical terms, there is evidence that non-adherence
doubles the rate of readmission (Valenstein et al., 2002, 2004;
Morken et al., 2008) which is about 4–6% according to Valen-
stein et al. (2006). However, recovery and long-term outcomes
were not correlated with adherence in a recent well-designed
discontinuation FEP study (Wunderink et al., 2009). Moreover,
administering antipsychotics every other day was not associated
with higher relapse rate or lower side effects in a randomized
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controlled trial on 35 stable patients (Remington et al., 2011),
suggesting that in some patients sub-optimal implementation
of prescriptions might represent a form of lay dosage optimiza-
tion.
Clinicians can increase medication adherence in schizophrenia
patients via prescription of long-acting injectable antipsychotics
or non-pharmacological interventions as cognitive behavioral
therapy, psychoeducation, family intervention, and motivational
approaches (Zhornitsky and Stip, 2012). Recently, technolog-
ically sophisticated electronic reminder devices and electronic
pill dispensers have been developed (Diaz et al., 2001). Among
these, the Medication Events Monitoring System (MEMS®) has
attracted the most interest in the literature (Byerly et al., 2005;
Remington, 2008; Acosta et al., 2009; Lee et al., 2011). It con-
sists of a cap containing an electronic chip that records openings
of the bottle; the cap contains a liquid crystal display (LCD)
screen that shows the number of times the bottle has been
opened in the day and hours since its last opening. Thus, it is
imprecise because it can be opened more or less often than nec-
essary. Also, its main purpose is only to monitor rather than
to improve management of adherence. Studies in schizophre-
nia that have quantiﬁed implementation of drug regimen with
MEMS® have found that between 41.2 and 59% of patients take
>70% of it (Byerly et al., 2007, 2008; Remington et al., 2007;
Acosta et al., 2009).
There is a lack of objective tools to precisely and speciﬁcally
assess the antipsychotic adherence ratio (AAR = number of pills
taken × 100/number of pills prescribed, a quantiﬁcation of imple-
mentation). In their systematic review of assessments tools of
antipsychotic adherence, Velligan et al. (2006) highlight that 77%
of the methods reported in the literature are self-reported and
indirect, whereas only 23% reported using an objective and direct
assessment like counting pills, measuring blood or urine concen-
tration, and electronic monitoring. Although it provides indirect
and self-rated measures, the Brief Adherence Rating Scale (BARS)
is a reliable tool to detect sub-optimal implementation of the dos-
ing regimen in schizophrenic patients. It has demonstrated good
reliability, sensitivity, and speciﬁcity relative to MEMS® (Byerly
et al., 2008). According to this scale, the AAR is about 49.5% in
schizophrenia. Yet, self-evaluation may over-estimate the real AAR
(Byerly et al., 2007).
In summary, non-adherence is a core problem in schizophre-
nia, but there is no validated tool to quantify implementation of
drug regimen in real time, and there is a lack of effective tool to
improve management of adherence in these patients. Recently,
an electronic, smart, 7-days pill dispenser named DoPill® was
developed by Domedic in Quebec to simultaneously quantify and
help patients with implementation. When we learned its existence,
we immediately wondered if its potential could help our patients
suffering from schizophrenia.
In the present randomized trial, we used the DoPill® to pro-
vide estimates of AAR in FEP patients as well as to quantify
implementation in real time. We hypothesized that this smart pill
dispenser would provide objective and direct measures of imple-
mentation comparable with those found with the BARS, and that
the reminders would help patients improve their management
implementation of the drug regimen.
MATERIALS AND METHODS
PARTICIPANTS
Participants with schizophrenia according to the fourth edition
of Diagnostic and Statistical Manual of Mental Disorders IV
(DSM-IV) criteria were recruited at the Institut universitaire en
santé mentale de Montréal between January 2008 and September
2010. Patients were randomized in two groups. The experimen-
tal group used the DoPill® during 6 weeks, and the control
group continued to take their treatment as usual (TAU; Sablier
et al., 2009). The study was approved by the Institut universitaire
en santé mentale de Montréal’s ethics committee and a signed
informed consent obtained from all participants prior to study
entry.
THE DoPill®
DoPill® is an electronic dispenser with 28 compartments covered
by a dynamic membrane which allows events detection (Figure 1).
Each compartment can contain multiple pills. The patient’s phar-
macist is responsible for programming the device, doing the usual
safety checks, and dispending the medication as prescribed. Visual
and sound alarms alert the user when it’s time to take medica-
tion and the compartment from which it must be taken. Finally,
sensors record the time of opening and upload the data to a
secure server on Internet which calculates an adherence ratio (pill
taken/pills given), and where clinicians can consult the adherence
in real time. Ten prototypes were provided free of charge by the
manufacturer.
PROCEDURE
Study protocol consisted of three visits: one baseline, one at
6 weeks, and one at 8 weeks. Patients were evaluated with
the BARS and the positive and negative syndrome scale for
schizophrenia (PANSS) to assess DoPill’s® impact on psychi-
atric symptoms. The patient and clinician-rated measure of
FIGURE 1 | DoPill® – an intelligent electronic pill dispenser.
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drug adherence by the BARS is separated in two steps. Initially,
the clinician asks the patient how often he tends to forget to
take medication. Subsequently, it’s the clinician that indicates
the proportion of medication he/she believes that the patient
consumes.
STATISTICAL ANALYSIS
The DoPill® software calculated AAR for all patients, and com-
puted the mean adherence rate of antipsychotics in the experi-
mental group. This resultwas statistically comparedwith theBARS
in both group assignments. Mean adherence rate was also com-
pared numerally with AAR found in the literature using MEMS®.
Proportions of patients with <70 and <90% AAR was also com-
puted, and compared numerally with AAR found in the literature
using MEMS®. The later is adapted from Weiden et al. (2004) who
found that under <70% of mean possession ratio (a composite
of initiation, implementation, and discontinuation), and <90%
persistence, 8.5 and 10.6% more patients are hospitalized over
one year, respectively. For the sake of clarity, patients with <70%
AAR are considered non-adherent. Cost of non-adherence was
estimated by the cost of wasted pills.
Descriptive statistics were used for baseline sociodemographic
and clinical characteristics of patients, for cost analysis, and for
proportion of patients with <70 and<90% AAR.
The results in the BARS did not follow a normal distri-
bution since most scores fell toward 100% adherence. How-
ever, a Brown–Forsythe test allowed us to verify homogeneity
of variance. Repeated measures ANOVA, with adherence rate,
BARS, group and visit number as variables, were preformed
with the non-parametric Scheirer–Ray–Hare test extension of
the Kruskal–Wallis test. The level of signiﬁcance for two-sided
hypothesis tests was set at a P-value less than 0.05. The SPSS
17.0 (Chicago, IL, USA) statistical software was used for all
analyses.
RESULTS
PARTICIPANTS
Completion of the study was 26/36 in the experimental group,
and 21/28 in the TAU group. Group sizes differ because of
chance in the randomization process, and the sample size is mod-
est because of time restrictions related to academia and human
resources. Dropout reasons were varied: in the experimental
group, theDoPill® sometimes had technical problems and patients
dropped out, some patients changed their minds when they were
randomized to TAU, and others were hospitalized.
Baseline sociodemographic and clinical data are shown in
Table 1. No signiﬁcant differences were noted for age, education,
illness duration or PANSS positive, negative and general scores
between patients randomized to the DoPill® and the TAU groups.
All were outpatients suffering from moderate illness. Although the
patients were recruited from a FEP program, mean age and dura-
tion of illness were 38 and 11 years, respectively, in the DoPill®
group, and 35 and 9 years, respectively, in the TAU group. In
the DoPill® group, antipsychotic prescriptions were as follows
(six patients were on antipsychotic polypharmacy): olanzapine
(n = 7), clozapine (n = 7), quetiapine (n = 4), ziprasidone (n = 3),
risperidone (n = 2), haloperidol (n = 2), perphenazine (n = 2),
Table 1 | Baseline sociodemographic and clinical characteristics of
randomized patients.
DoPill® (n = 26) TAU (n = 21) Statistics
Age 38 (10) 35 (9) t = 1.32; p = 0.19
Education 12 (3) 11 (3) t = 0.98; p = 0.33
Illness duration 11 (10) 9 (8) t = 0.76; p = 0.45
PANSS positive 16 (5) 17 (4) t = –0.69; p = 0.5
PANSS negative 19 (5) 18 (5) t = 0.58; p = 0.57
PANSS general 40 (7) 39 (5) t = 0.77; p = 0.45
Gender
Male 62% 76%
Female 38% 24%
Diagnosis
Schizophrenia 71% 84%
Other* 29% 16%
*Schizoaffective or schizophreniform disorder.
paliperidone (n = 1), zuclopenthixol (n = 1). In the TAU group,
antipsychotic prescriptions were as follows (eight patients were
on antipsychotic polypharmacy): olanzapine (n = 8), clozapine
(n = 6), risperidone (n = 5), quetiapine (n = 3), ziprasidone
(n = 2), haloperidol (n = 2), perphenazine (n = 2), aripiprazole
(n = 1), ﬂuphenazine (n = 1). Concomitant medications were
allowed and dispensed in the DoPill® by the pharmacist as usual.
MEASURING ADHERENCE WITH BARS
The BARS results are shown in Table 2. The repeated mea-
sures ANOVA failed to reveal an interaction between the factors
“group” and “time” for the BARS patient self-report adherence
rate (P = 0.73). On the other hand, a repeated measures ANOVA
revealed an interaction between group and visit for the BARS clin-
ician rating (P = 0.01). Contrast tests allowed us to verify that this
difference is present between both baseline and visits 1 and visits 2.
MEDICATION ADHERENCE WITH DoPill® VERSUS MEMS®
Adherence rates recorded by DoPill® for each patient are presented
in Figure 2. In this sample, the mean AAR recorded by DoPill®
over the 6 weeks of use was 66.6% [secure digital (SD) 35.1].
Table 2 | Adherence ratings across visits (BARS).
Baseline,
mean (SD)
Visit 1,
mean (SD)
Visit 2,
mean (SD)
P -
value*
Clinician rating (DoPill®)
Adherent (n = 12)
Non-adherent (n = 8)
92.6 (7.6)
95.9 (3)
98.3 (3)
86.4 (11.1)
96.3 (3.5)
93.3 (9.5)
P = 0.01
Self-report (DoPill®)
Adherent (n = 13)
Non-adherent (n = 11)
95.9 (8.1)
93.3 (11.2)
96.2 (11.1)
95.2 (6.9)
99 (2.5)
94.9 (5.2)
P = 0.73
*Interaction (visit × group).
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FIGURE 2 | Adherence to treatment as recorded by the DoPill®.
The proportion of patients with<70 and<90% AAR was 46 and
54%, respectively, whichwas consistent with 41.2–59% foundwith
MEMS® in the literature.
Potential heterogeneity
In the data set, extracted for each patient, we noticed that some
patients did not take all the medication prescribed by the psy-
chiatrist and choose or selected only some of the pills from the
dispenser. As illustrated in Table 3, we can see that for instance in
subject EET-20 venlafaxine was 38% taken versus 43% for procy-
clidine. This can also be explained if the patient forgot most often
morning drugs but not evening ones because of environmental or
time factors.
Cost
Cost related to non-adherence (pills actually not taken), was
estimated at 15024.68 CAN $/year for the 26 patients we followed.
See Table 3 for calculations for two subjects.
DISCUSSION
This randomized trial revealed that the DoPill® is a well-designed,
technologically sophisticated, and highly functional electronic pill
dispenser. The device provided estimates of implementation in
FEP patients from the proportion of doses taken on time, which
were in accordance with those found in the literature (Diaz et al.,
2001; Lacro et al., 2002; Byerly et al., 2005; Remington, 2008; Lee
et al., 2011). By contrast, BARS scores were overly optimistic
(86–99%) for adherent and non-adherent patients across vis-
its. Previous research has shown a high degree of concordance
between BARS and MEMS® over a period of 6 months (Byerly
et al., 2008). However, in our study the scale was ﬁlled by a nurse,
an ergotherapist or a specialized educator, but not by the psy-
chiatrist of the patients. Our results suggest that the BARS is
more reliable if ﬁlled by the psychiatrist of the patient. Recently,
another group from Montreal evaluated how much agreement
exists between self-reports of adherence to antipsychotic medi-
cation and objective or derived measures of adherence in FEP
Table 3 | Estimation of non-adherence costs in our sample of schizophrenia patients (N = 17). Example of two patients from the “Enriched
Environment withTechnology” (EET) group.
Patient # Medication AAR (%) Price per unit ($/u) Unused costs per year (CAD)
EET-01 (AAR = 96.08%) COGENTIN 2 mg 93.33 0.23 $ 35.62
SEROQUEL XR 400 mg 100 4.56
ZELDOX 40 mg 94.74 1.94
ZELDOX 60 mg 92.31 1.94
SEROQUEL XR 200 mg 100 2.46
EET-20 (AAR = 42%) PMS-PROCYCLIDINE 2.5 mg 42.86 0.24 $ 1,638.43
HALOPERIDOL 2 mg 42.86 0.12
HALOPERIDOL 5 mg 42.86 0.18
GLUCOPHAGE 500 mg 40.82 0.39
VENLAFAXINE XR 150 mg 38.78 2.24
GEN-CLOZAPINE 50 mg 42.86 0.7
GEN-CLOZAPINE 200 mg 42.86 1.9
Total (N = 17) 63.51 $ 9,823.83
AAR, antipsychotic adherence ratio.
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(Lepage et al., 2010). Adherence was measured in 81 FEP subjects
on a monthly basis by reports from patients, clinicians, family, and
pill counting. Adherence (74%) as measured by patient report, pill
count, and clinician reports were in good agreement with each
other and all of these measures were highly correlated to con-
sensus adherence. The authors showed that patient or clinician
reports gave a reasonable estimate of medication adherence in
FEP, and that introducing pill counting was a better accurate mea-
surement. We think that this high score of adherence is probably
optimistic.
Data from DoPill® revealed a mean adherence rate of 67%,
which is highly consistent with previous data on MEMS® (Byerly
et al., 2005; Remington, 2008; Acosta et al., 2009; Lee et al., 2011).
Additionally, when treated as a dichotomous variable (<70% cri-
teria), 46% of patients were found to be non-adherent using the
device. At outset, it was reasonable to expect that non-adherence
rates obtained with DoPill® would be substantially lower over
those obtained with MEMS® because the former employs elec-
tronic cues designed to counter forgetfulness. Although we did
not compare them directly, we believe they are technically com-
parable for measurement because they both record the opening
of the pill compartments. Despite the cues, we found compa-
rable rates of non-adherence using both devices at the <70%
threshold. Looking at the raw scores in Table 2, we can see
that most of adherent DoPill® patients are ultra-adherent (i.e.,
98–100%), suggesting that the device may maximize adher-
ence in those already adherent, while leaving the overall rates
of non-adherence (<70% criteria) at similar levels. In support,
the BARS clinician ratings showed that adherent patients evi-
denced signiﬁcantly greater improvement in adherence, relative
to non-adherent patients over the 6 weeks. Taken together, these
preliminary ﬁndings suggest that there may be a limit on the
beneﬁt that electronic aids can have for increasing the imple-
mentation of the drug regimen in non-adherent schizophrenia
patients. That is, we can maximize it in “responsive” FEP patients,
but other interventions arenecessary to reach the∼46%of patients
who are non-adherent (<70% criteria), despite electronic aids.
This is compatible with a model of ﬁve patient prototypes of
adherence: patients with (1) good adherence for the right rea-
sons, (2) with good adherence for the wrong reasons, (3) with
passive adherence, (4) with reluctant and tenuous adherence,
and (5) with unwillingness to take medications (Freudenreich
and Tranulis, 2009). Indeed, the DoPill® is likely to improve
the management of adherence only in the ﬁrst three proto-
types, and to be of little beneﬁt for the later two, who are also
probably likely to be completely non-adherent (i.e., not simply
forgetful).
To compare the DoPill® with other electronic pill dispensers,
we searched the World Wide Web and PubMed. We found that
the most popular devices are simple alarm clocks with vibra-
tion, and the most sophisticated are alarms that also dispense
the medication and can call a caregiver if forgotten. However,
MEMS® excluded, there are no other device that integrates the
pharmacist in the process, and no other device that were stud-
ied in a clinical trial. This professional is the most important to
ensure that drug regimens are safe and effective, and it’s crit-
ical that he validates the ﬁnal disposition and identiﬁcation of
drugs before administration. This is a signiﬁcant strength of the
DoPill®, because it’s the patient’s pharmacist who prepares and
identiﬁes the 7 days medication card, and who sends the data in
the patient’s device by Internet. All this is integrated seamlessly in
the pharmacy software, with the usual security checks. MEMS®
remains the most studied device to monitor adherence, but it
does not include reminders, and every dosage of a drug needs a
separate device. DoPill® has the potential to replace it, because
it includes reminders, monitors opening in real time, can com-
municate with a provider, and can dispense multiple drugs at a
time.
The study has also some limitations. The imbalance between
the two groups as well as the low completion rate have to
be considered. Results could have been different with a big-
ger sample size, a fully functional DoPill®, and longer duration
of the trial. Unfortunately, every trial or study in technology
or device development can be confronted with time restrictions
to complete the study due to the evolution of the device. For
many people who suffer from reduced cognitive and intellec-
tual capacity, the complexity of user interfaces, their logic and
conﬁguration appear to be the biggest challenge, but many design-
ers and manufacturers still overlook these problems. Therefore,
simplifying user interfaces should be a designer’s and software
engineer’s main focus, but this limits clinical trial duration
to give the opportunity to developers to test new improved
versions.
Universal design is a term which refers to accessible, com-
prehensible, and intuitive design solutions for all, regardless of
age, ability, or status, but also solutions that avoid stigmatiza-
tion and digital exclusion. In schizophrenia it is crucial. Today
more than ever, designers are sensitive to the need for simple
and meaningful products, especially considering the complex-
ity and continuously changing nature of digital products and
devices. In our trial, the ﬁndings and patient feedback were con-
tinuously shared with the manufacturer to improve our patient’s
safety and satisfaction with the DoPill®. It is presently used
in clinical practice, because physical and psychological barri-
ers have been reduced, and its user interface is intuitive and
decipherable.
CONCLUSION
Overall, results from this randomized study indicate that DoPill®
is a valid tool to quantify adherence. It also has the added advan-
tage of being able to track implementation daily, in ecological
conditions, and to send a signal to the pharmacist or another
person in case of problem or missed dose. It is also clear with
the high costs of non-adherence that a constant monitoring of a
patient’s adherence is extremely useful. In FEP patients, reported
rates of non-adherence [39% with Coldham et al. (2002); 33%
with Kamali et al. (2006)] varied with time and typically increased
during months six to twelve (Lepage et al., 2010). We suggest that
it would be of value to use DoPill®, or any smart electronic pill
dispenser with live monitoring, as a standardized objective mea-
sure of adherence in clinical trials. A longer trial is needed to
conﬁrm this, but in the meantime, these devices can be used
to help selected patients to successfully manage their medication
regimen.
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